Abstract

[Autom. eng. transl.] The objective of the following report is to provide, using the HTA methodology, an overview of the clinical, economic, organizational, social, ethical and legal impact of using Emicizumab with subcutaneous formulation compared to the intravenous formulation that it concerns standard bypassing agents in the treatment of Hemophilia A with inhibitors. The expected result is to carry out an evaluation according to the Health Technology Assessment (HTA) methodology on the adoption of Emicizumab, indicated for patients with hemophilia A with inhibitors, which allows to facilitate the decision-making process, specifically, from the perspective of the evaluation commissions ( regional / local doctors, pharmacists, economists, budget holders) on the adoption of Emicizumab in regional / local handbooks and diagnostic-therapeutic assistance programs (PDTA).
Translated title of the contribution[Autom. eng. transl.] Full HTA of Emicizumab
Original languageItalian
Number of pages207
Publication statusPublished - 2019

Keywords

  • HTA
  • emofilia

Fingerprint

Dive into the research topics of '[Autom. eng. transl.] Full HTA of Emicizumab'. Together they form a unique fingerprint.

Cite this